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SUMMARY
Introduction: Infection by Mycoplasma pneumoniae is becoming more frequent at younger ages. It appears as a generally
benign and unspecific clinical condition of respiratory symptoms and sometimes responsible for a broad spectrum of
extrapulmonary manifestations.
Objective: To describe demographic, clinical, laboratory, and treatment characteristics of pediatric-age patients with
positive serology for M. pneumoniae diagnosed at the Pablo Tobón Uribe Hospital (HPTU) during the 2006-2008 period.
Materials and methods: Observational, retrospective study, which describes the demographic, clinical, laboratory, and
treatment characteristics of patients from 1 month to 14 years of age with positive IgM for M. pneumoniae seen at HPTU
during September 2006 and November 2008.
Results: We reviewed 305 clinical charts of patients with positive IgM for M. pneumoniae. The average age was 5.15
years ± 3.62 SD. Cough (87.5%), fever (65.9%), rhinorrea (39.3%), and respiratory difficulty (38%) were the most frequent
clinical findings. Extrapulmonary compromise was mainly manifested in the skin (12.8%), the central nervous system (CNS)
(3.6%), and osteomuscular system (3.9%). Auscultation and thoracic X-ray were normal in 33.1% and 30.8% of the patients,
respectively. Episodes of asthma exacerbation were related to infection by Mycoplasma in 35% of the cases. A total of 51%
of the patients required hospitalization with an average stay of seven days. All the patients received antibiotic treatment;
clarithromycin (75.8%) was the antibiotic of choice.
Conclusion: Infection by M. pneumoniae has a broad range of clinical manifestations, requiring a high index of clinical
suspicion and an active search for extrapulmonary compromise given that in our realm there is no specific diagnostic method
for the acute infection.
Keywords: Mycoplasma pneumonia; Pneumonia; Extrapulmonary manifestations; Children.
Colomb Med. 2011; 42: 138-43
Características clínicas y epidemiológicas de pacientes pediátricos con serología positiva para  Mycoplasma
pneumoniae, atendidos en un hospital de tercer nivel  durante el período 2006-2008
RESUMEN
Introducción: La infección por Mycoplasma pneumoniae es cada vez más frecuente a edades tempranas. Se presenta
como un cuadro clínico de síntomas respiratorios generalmente benigno e inespecífico y en ocasiones es reponsable de un
amplio espectro de manifestaciones extrapulmonares.
Objetivo: Describir las características demográficas, clínicas, de laboratorio y el tratamiento de pacientes en edad
pediátrica con serología positiva para M. pneumoniae diagnosticados en el Hospital Pablo Tobón Uribe (HPTU) durante el
período 2006-2008.
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Materiales y métodos: Estudio observacional, retrospec-
tivo, que describe las características demográficas, clínicas,
de laboratorio y tratamiento de pacientes de 1 mes a 14 años
de edad con IgM positiva para M. pneumonie atendidos en el
HPTU entre septiembre de 2006 y noviembre de 2008.
Resultados: Se revisaron 305 historias clínicas de pa-
cientes con IgM positiva para M. pneumoniae. La edad
promedio fue 5.15 años ± 3.62 DE. La tos (87.5%), fiebre
(65.9%), rinorrea (39.3%) y dificultad respiratoria (38%)
fueron los hallazgos clínicos más frecuentes. El compromiso
extrapulmonar se manifestó sobre todo en piel (12.8%),
sistema nervioso (3.6%) y sistema osteomuscular (3.9%). La
auscultación y la radiografía de tórax fueron normales en
33.1% y 30.8% respectivamente. Los episodios de exacerba-
ción del asma se relacionaron con infección por Mycoplasma
en 35% de los casos. Del total de niños, 51% necesitó
hospitalización con un promedio de estancia de 7 días. Todos
los pacientes recibieron tratamiento antibiótico, siendo el de
elección claritromicina (75.8%).
Conclusión: La infección por M. pneumoniae posee una
amplia gama de manifestaciones clínicas que requiere un alto
índice de sospecha clínica y una búsqueda activa de compro-
miso extrapulmonar porque en Colombia no se cuenta con un
método diagnóstico específico para la infección aguda.
Palabras clave: Mycoplasma pneumoniae; Neumonía;
Manifestaciones extrapulmonares; Niños.
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In recent decades, respiratory infections have
surpassed diarrhea as the main cause of morbidity in
developing nations. Particularly, Mycoplasma pneu-
moniae has been shown to be a frequent cause of
pneumonia in children and young adults; although
diagnosis at younger ages has recently increased1-4.
Mycoplasma pneumoniae was first described in
humans in 1942 by Eaton et al.1 It is an extracellular
bacterium from the Mycoplasmataceae family, which
is exclusively human and has universal distribution2. It
is characterized for lacking a cell wall3 and not
responding to the Gram staining.
The presentation of the infection is noted in
epidemiological cycles every 3-5 years, with a frequency
of 2 cases/1000 individuals/year5-8. In our realm, the
frequency of infection by this microorganism is not
well established. In the United States and Europe, it is
responsible for up to 40% of community-acquired
pneumonias (CAP) and 18% of pneumonias requiring
hospitalization2,9-12. In Asia and Africa, it has been
reported that 44% and 34% of the CAP in children are
caused by M. pneumoniae. Latin American studies
reported a prevalence of CAP due to Mycoplasma
pneumoniae of 15% and 7% in Argentina and Panama,
respectively9.
Infection due to M. pneumoniae is considered benign
and self-limited; it may be asymptomatic in 20% of the
cases3,11 or run its course with extrapulmonary manifes-
tations (meningoencephalitis, polyneuropathy, myelitis,
arthritis, vasculitis, hemolytic anemia) in 15 to 25% of
the cases1.
The immune response is manifested by the rapid
production of antibodies responding to the organism’s
protein and glycolipid antigens, with a maximum
concentration reached in 3 to 6 weeks and a decrease
starting after 4 to 6 months11.
We described the epidemiological, clinical, labo-
ratory, and treatment characteristics of patients with
positive IgM for M. pneumoniae in the pediatric service
at Pablo Tobón Uribe Hospital (HPTU) in the city of
Medellín, Colombia during period between September
2006 and November 2008.
MATERIALS AND METHODS
This was an observational, retrospective study
describing the epidemiological and clinical charac-
teristics, along with laboratory results and treatment of
pediatric-age patients (1 month to 14 years of age) with
positive serology for M. pneumoniae in Pablo Tobón
Uribe Hospital from September 2006 to November
2008.
During the study period, 457 positive IgM results for
M. pneumoniae were included for patients between 1
month and 14 years of age. A total of 152 patients were
excluded; 17 because their age was outside the range of
the study, 90 had incomplete information, and 45 had
no hospital records at the Institution. We reviewed 305
clinical charts and the information was recorded onto a
previously designed format, which included demo-
graphic characteristics, clinical manifestations, imaging,
laboratory results, and treatment.
The information gathered was tabulated onto a data
base on Microsoft Excel® 2007, and exported to the
SPSS version 15.0 statistical package (Chi IL) to present
the results as mean and standard deviations.
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The research was carried out according to Resolution
N° 008430 of 1993 by the Ministerio de la Protección
Social de Colombia, which establishes the scientific,
technical, and administrative norms for health research.
The Research and Ethics Committee at HPTU approved
the research work, and steps were taken to protect the
patients’ identities and dignity and that of their families.
The study is classified as research free of risk, given
that no action is taken on the patients and only a
documentary and retrospective revision is made.
RESULTS
Distribution by gender was 148 girls (48.5%) and
157 boys (51.5%); the age range was between 1 month
and 14 years, with a mean of 5.15 ± 3.62 SD (4-year
median). Some 95% of the patients were from the city
of Medellín and its metropolitan area and 5% were from
the rural area of the department of Antioquia.
A total of 63% of the patients attended school and
only 35% had a history of asthma. Regarding the
clinical condition at the time of consultation, we found
a variable evolution, with a symptom onset median of
4 days (range from 1 to 150 days).
Cough was the most frequent symptom (87.5%),
followed by fever (66%), rhinorrea (39.5%), and
respiratory difficulty (38%) (Table 1). Other symptoms
reported were pharyngitis (15%), cephalea (11%),
odynophagia (9.5%), otitis (8%), otalgia (6%),
conjunctivitis (4.3%), arthralgias (4%), and myalgia
(3.6%) without significant difference in the frequency
of presentation in the different age groups. Neurological
symptoms were detected in 11 (3.6 %) patients, among
which convulsions (27%), polyneuropathy (18%), and
encephalopathy (9%) were the most frequent. Cutaneous
manifestations were reported in 12.8% of the cases:
exanthema (74.4%), wheal (5%), rash (2.6%), and
vesicles (2.6%).
Pulmonary auscultation was normal in 33.1% of the
patients. Among the abnormal findings there were only
sibilance in 15% and a combination of pulmonary noise
in 45% of the patients (Table 1).
Upon admission, hemoleukogram was requested
from 241 patients (78.6%), where the leukocyte avera-
ge was 11.488/mm3 and the differential was found
normal in most patients. The C reactive protein (CRP)
was carried out in 58% of the patients, with a median of
Table 1
Clinical and ausculatory manifestations in
305 children with infection by Mycoplasma
pneumoniae at hospital of third level 2006-2008
  Clinical manifestation                   N=305       %
 Cough 267 87.5
 Fever 201 65.9
 Rhinorrhea 120 39.3
 Respiratory difficulty 116 38
 Hypoxemia (sat <92%) 65 21.3
 Pharyngitis 46 15.0
 Cephalea 33 10.8
 Odynophagia 29 9.5
 Otitis 24 7.8
 Otalgia 18 5.9
 Conjunctivitis 13 4.2
 Arthritis 12 3.9
 Myalgia 11 3.6
 Normal auscultation 101 33.1
 Wheezing 46 15
 Wheezing with prolonged expiration 31 10.1
 Wheezing with crepitus 22 7.2
 Crepitus alone 19 6.2
 Wheezing with ronchi 19 6.2
 Ronchi alone 14 4.5
 Other unspecified findings 54 17.7
1.4 mg/dl (ranging from 0 to 39 mg/dl). Thoracic X-rays
were ordered on 201 patients, 62 radiographs were
reported normal (32%) and among the abnormal
findings, the most frequent were interstitial infiltrates
(28%) and air trapping (11%), (Table 2). Other
diagnostic aids were requested from 58 patients;
computerized axial tomography (CAT) of paranasal
sinuses presented abnormal findings in 63% of the
cases. Electromyography, skin biopsy, and cerebrospinal
fluid (CSF) exam were requested from less than 1% of
the patients.
A total of 51% of the patients were hospitalized,
10% in the special and intensive care unit. Supple-
mentary oxygen was required for 33% of the patients
and 1.3% needed mechanical ventilation. The average
hospital stay was of 7 days with an interval between 1
and 137 days. Clinical records revealed droplet isolation
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in 134 (45.5%) of the cases. All the patients received
antibiotic treatment; the antibiotic of choice was
Clarithromycin (75.7%), followed by erythromycin
(16.1%) and azithromycin (8.2%). Doctors ordered
bronchodilators for 80% of the patients, steroids for
66% (systemic 36%, inhaled 36%, and both ways of
administering 28%), analgesics and antipyretics for
47.3%, and antihistamines for 24.5% of the patients
(Table 3).
DISCUSSION
Mycoplasma pneumoniae has always been
considered one of the main causes of respiratory infection
in school-age populations. However, during the last
two decades it has been more frequently identified at
earlier ages12,14,15. In the current study, 63% of the
patients with positive serology were less than five years
of age and coincidentally the same percentage was of
school age.
In general, manifestations of infection by this
microorganism are variable and unspecified and the
clinical condition has a gradual onset during days or
months11,16. Regarding the evolution of symptoms, the
findings in this study do not differ with that reported in
the literature and the frequency is similar to that found
by Waites et al.13, with respect to fever, cough,
compromise of the general status, cephalea, and
odynophagia6,12,15.
Infection by M. pneumoniae has a known role as
triggering of asthmatic exacerbations in children17-19,
Biscardi et al.2, reported infection by this microorganism
as the cause of 50% of acute crisis of patients with a
history of asthma and as a risk factor for unfavorable
evolution in 20% of these2. In this investigation, 35% of
the patients had a history of asthma but the infection
was not identified as triggering the crisis because such
was not one of the objectives of the study.
Although respiratory manifestations predominate
in acute infection by M. pneumoniae, extrapulmonary
compromise is reported in up to 25% of the cases,
occurring even after the respiratory disease or in the
absence of such10,13,15,19,21. We noted the skin as the
most frequently committed organ at extrapulmonary
level, followed by the affectation of the CNS and the
osteomuscular system.
Findings of physical exam are unspecific. In this
work, we found normal auscultation in 33% of the
patients and sibilance in 15%; however, Othman et
al.11,20, describe that sibilance is found in over a third of
the CAP caused by M. pneumoniae in hospitalized
children11-21.
Isolating M. pneumoniae via oropharyngeal or
nasopharyngeal aspirate culture is considered the method
of choice for the diagnosis of acute infection. Its
usefulness is limited in clinical practice because it
requires from 10 to 14 days. Polymerase chain reaction
(PCR) is one of the alternatives in confirming the
diagnosis8,10,22, but it is not available in our realm.
The IgM for Mycoplasma may be used via the
enzimoinmunoensayo22 technique, but this requires
comparison of paired sera to confirm the diagnosis of
acute infection. In the current investigation, the
Table 2
Findings through thoracic X-rays requested for
201 patients with infection by Mycoplasma
pneumoniae at hospital of third level 2006-2008
   Finding                                        N=201    %
Normal 62 30.8
Interstitial infiltrate 57 28.3
Interstitial infiltrate with air trapping 21 10.4
Consolidation 15 7.4
Air trapping 13 6.4
Combined radiologic anomalies 33 16.7
Table 3
Symptomatic treatment of patients with infection
by Mycoplasma pneumoniae
at hospital of third level 2006-2008
 Symptomatic treatment      n/N       %
Bronchodilators 238/298 79.8
Steroids 197/297 66.0
Inhaled route 71/197 36.0
Systemic route 71/197 36.0
Both routes 55/197 28.0
Analgesic/antipyretic 141/298 47.3
Oxygen 99/298 33.0
Antihistamines 73/298 24.4
Ipatropium bromide 69/298 23.0
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technique used in measuring IgM (immunocard R
Mycoplasma) has a specificity of 90 ± 3% and a
sensitivity of 88 ± 6%, but in positive values which do
not distinguish between current or recent infection
(<12 months of evolution). Souliu et al.11, suggest that
for the diagnosis of M. pneumoniae as etiology of a
respiratory condition, IgM through the ELISA method
should be confirmed via PCR or culture; increased
immunoglobulin M in paired samples or levels of IgG
>400 U/ml21,23. Our study did not conduct diagnostic
confirmation because of the retrospective character and
because these techniques were not available in the
clinical practice. Long-term persistence of seropositivity
in spite of adequate antibiotic treatment of the
infection4,10,11,24 hinders the interpretation of the results
because of the high percentage of false positives.
We found no specific alterations in para-clinical
exams, which permit distinguishing the infection by M.
pneumoniae from that produced by other micro-
organisms. The leukocyte count was normal or slightly
high9,16 with differential and PCR within the normal
range12,16. The thoracic X-ray reveals a variety of patterns
that hinder diagnostic orientation merely through
images, finding it normal in 31% of the cases2,6,11,12,16,21.
In different observational studies, hospitalization in
infection by M. pneumoniae is required in approximately
20% of the cases2,12,13. Perhaps in our realm, the report
that over half of the patients require hospitalization
may be due to the possibility of out-patient follow up
and treatment cannot be assured.
Infection by M. pneumoniae is often self-limited;
with improvement of symptoms within the first 10
days2,16. In spite of this, it was found that all the patients
in this study received antibiotic treatment. Some
literature reviewed justify antibiotic treatment,
asseverating that it limits morbidity by pneumonia,
shortens the duration of the symptoms, and decreases
the frequency of recurrent sibilance episodes, although
it does not reduce the risk of transmission9.
Although M. pneumoniae is susceptible to antibiotics
like tetracycline and quinolones, it is treated as a first
therapeutic option with macrolides10-12,15,16 because of
its safety during pediatric age, clinical and radiological
improvement, along with the microbiological
erradication2,17,25. The symptomatic treatment (non-
antibiotic) does not reveal sufficient evidence regarding
improvement, duration of symptoms, and time of hos-
pital stay of patients with non-complicated infections.
In conclusion, infection by M. pneumoniae has a
broad variety of manifestations, which turn out to
unspecific to reach a clinical diagnosis. A high index of
suspicion is required to avoid mainly extrapulmonary
complications, which are the most serious. Hence, to
confirm the infection and optimize the treatment
regarding the rational use of antibiotics, it is indispen-
sable to have a method with a high level of sensitivity
and specificity for which IgM, without comparing
labels in paired sera, is not suitable. Based on this, we
suggest the need to conduct a prospective study to
compare the positive results of IgM for M. pneumoniae
and PCR for the diagnosis of acute infection.
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